Clinical Trials Browser

Phase 1/2 × Brentuximab Vedotin × Clear all

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1/2 Active not recruiting

59 enrolled 63 charts

Hodgkin Disease

NCT03187210 2025-03-30

BAL

Phase 1/2 Suspended

Lymphoma

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02572167 2022-11-08

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

93 enrolled 13 charts

Hodgkin Disease

NCT02098512 2022-10-27

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Phase 1/2 Unknown

Hodgkin Disease

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

Hodgkin Disease, Recurrence

NCT01780662 2021-10-28

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

46 enrolled 18 charts

Hodgkin Disease

NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Phase 1/2 Terminated

20 enrolled 17 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01657331 2020-07-17

SGN+Benda

Phase 1/2 Completed

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02729961 2019-10-10

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Phase 1/2 Withdrawn

Lymphoma, Large-Cell, Anaplastic

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

Hodgkin Disease, Lymphoma

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Phase 1/2 Terminated

5 enrolled 9 charts

Lymphoma, Large-Cell, Anaplastic

NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1/2 Withdrawn

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01620229 2014-04-21

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Phase 1/2 Completed

DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating